Real-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study
Open Access
- 8 December 2025
- journal article
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e77661
Abstract
Background: Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. Objective: We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. Methods: This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. Results: Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. Conclusions: The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. Trial Registration: International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 International Registered Report Identifier (IRRID): DERR1-10.2196/77661Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Progress on Prevention and Treatment of Cerebral Small Vascular Disease Using Integrative MedicineChinese Journal of Integrative Medicine, 2022
- Vascular Cognitive Impairment (VCI)Neurotherapeutics, 2022
- White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunitiesAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2019
- The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive DeclineCellular and Molecular Neurobiology, 2016
- Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factorsThe Lancet Neurology, 2008
- Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementiaNeurobiology of Aging, 2006
- Vascular parkinsonism — an updateJournal of the Neurological Sciences, 2006
- Galantamine for vascular cognitive impairmentCochrane Database of Systematic Reviews, 2006
- Rivastigmine in subcortical vascular dementiaJournal of the Neurological Sciences, 2002
- Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trialThe Lancet, 2002